Interdisciplinary Graduate Program in Human Toxicology,
Department of Pathology,
Division of Pharmaceutics and Translational Therapeutics,
College of Pharmacy,
Holden Comprehensive Cancer Center,
Department of Oral Pathology,
Radiology and Medicine,
College of Dentistry,
Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy,
Department of Oral Pathology, Radiology and Medicine, College of Dentistry
Andrean L. Simons has not added Biography.
If you are Andrean L. Simons and would like to personalize this page please email our Author Liaison for assistance.
Upregulated interleukin-6 expression contributes to erlotinib resistance in head and neck squamous cell carcinoma.
Molecular oncology Aug, 2015 | Pubmed ID: 25888065
2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells.
Cancer research Apr, 2007 | Pubmed ID: 17409446
Enhanced response of human head and neck cancer xenograft tumors to cisplatin combined with 2-deoxy-D-glucose correlates with increased 18F-FDG uptake as determined by PET imaging.
International journal of radiation oncology, biology, physics Nov, 2007 | Pubmed ID: 17967311
2-Deoxyglucose combined with wild-type p53 overexpression enhances cytotoxicity in human prostate cancer cells via oxidative stress.
Free radical biology & medicine Mar, 2008 | Pubmed ID: 18155176
Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism.
Free radical biology & medicine Jan, 2009 | Pubmed ID: 18983911
Mitochondrial electron transport chain blockers enhance 2-deoxy-D-glucose induced oxidative stress and cell killing in human colon carcinoma cells.
Cancer biology & therapy Jul, 2009 | Pubmed ID: 19411865
Inhibition of glutathione and thioredoxin metabolism enhances sensitivity to perifosine in head and neck cancer cells.
Journal of oncology , 2009 | Pubmed ID: 19746172
Glucose deprivation-induced metabolic oxidative stress and cancer therapy.
Journal of cancer research and therapeutics Sep, 2009 | Pubmed ID: 20009288
Erlotinib-mediated inhibition of EGFR signaling induces metabolic oxidative stress through NOX4.
Cancer research Jun, 2011 | Pubmed ID: 21482679
Regulation of pancreatic cancer growth by superoxide.
Molecular carcinogenesis Jul, 2013 | Pubmed ID: 22392697
Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism.
PloS one , 2012 | Pubmed ID: 23118946
The Justy mutant mouse strain produces a spontaneous murine model of salivary gland cancer with myoepithelial and basal cell differentiation.
Laboratory investigation; a journal of technical methods and pathology Jun, 2013 | Pubmed ID: 23608756
NOX4 mediates cytoprotective autophagy induced by the EGFR inhibitor erlotinib in head and neck cancer cells.
Toxicology and applied pharmacology Nov, 2013 | Pubmed ID: 23917044
EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.
Molecular cancer research : MCR Dec, 2013 | Pubmed ID: 24048704
MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Cancer research Apr, 2015 | Pubmed ID: 25712126
2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Oncology research , 2016 | Pubmed ID: 27178822
Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma.
Oncotarget Nov, 2016 | Pubmed ID: 27738319
Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.
Journal for immunotherapy of cancer 03, 2019 | Pubmed ID: 30890189
Impact of Nuclear Interleukin-1 Alpha and EGFR Expression on Recurrence and Survival Outcomes in Oral Squamous Cell Carcinomas.
Journal of oncology , 2019 | Pubmed ID: 31320902
A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.
Biomarker research , 2019 | Pubmed ID: 31346466
immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy.
Journal for immunotherapy of cancer 10, 2020 | Pubmed ID: 33060147
The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent.
Scientific reports Jan, 2021 | Pubmed ID: 33452311
Combining Doxorubicin-Loaded PEGylated Poly(Lactide-co-glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model.
ACS biomaterials science & engineering 05, 2020 | Pubmed ID: 33463284
Ketogenic Diet with Concurrent Chemoradiation in Head and Neck Squamous Cell Carcinoma: Preclinical and Phase 1 Trial Results.
Radiation research Jun, 2021 | Pubmed ID: 34087943
M. M. Hasibuzzaman1,2,
Kathleen A. Ross3,4,
Aliasger K. Salem1,4,5,6,
Balaji Narasimhan3,4,
Andrean L. Simons1,2,3,5,6,7
1Interdisciplinary Graduate Program in Human Toxicology, University of Iowa,
2Department of Pathology, University of Iowa,
3Department of Chemical and Biological Engineering, College of Engineering, Iowa State University,
4Nanovaccine Institute, Iowa State University,
5Division of Pharmaceutics and Translational Therapeutics, College of Pharmacy, University of Iowa,
6Holden Comprehensive Cancer Center, University of Iowa,
7Department of Oral Pathology, Radiology and Medicine, College of Dentistry, University of Iowa
Copyright © 2024 MyJoVE Corporation. 판권 소유